TRAIL, CXCL10 and CCL2 levels during long-term Interferon-β treatment of patients with multiple sclerosis correlate with flu-like adverse effects but do not predict therapeutic response

被引：31

作者：

Buttmann, Mathias

Merzyn, Comelia

Hofstetter, Harald H.

Rieckmann, Peter

机构：

[1] Univ Wurzburg, Dept Neurol, D-97080 Wurzburg, Germany

[2] Univ Dusseldorf, Dept Neurol, D-4000 Dusseldorf, Germany

[3] Univ British Columbia, Univ British Columbia Hosp, MS Clin, Vancouver, BC V5Z 1M9, Canada

来源：

JOURNAL OF NEUROIMMUNOLOGY | 2007年 / 190卷 / 1-2期

关键词：

multiple sclerosis; interferon-beta; TNF-related apoptosis-inducing; ligand; CXC chemokine IP-10; monocyte chemoattractant protein-1; adverse effects; biological markers;

D O I：

10.1016/j.jneuroim.2007.08.009

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

High serum levels of soluble TRAIL (sTRAIL) before or during the first year of Interferon-beta (IFN-beta) therapy were shown to predict an individual therapeutic response of patients with relapsing-remitting multiple sclerosis (RRMS). Here, we investigated whether sTRAIL plasma levels during long-term IFN-beta treatment correlate with future therapeutic response or adverse effects of treatment. Postinjection short-time bursts of sTRAIL were associated with flu-like symptoms and IP-10/CXCL 10 as well as MCP-1/CCL2 induction, and were detected after up to 6 years of continuous IFN-beta therapy. However, neither sTRAIL nor chemokine levels allowed prediction of one- and two-year clinical treatment response in 30 RRMS patients, prospectively followed by blinded investigators. (C) 2007 Elsevier B.V. All rights reserved.

引用

页码：170 / 176

页数：7

共 36 条

[31] Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an inhibitor of autoimmune inflammation and cell cycle progression [J].